Decibel Therapeutics Inc is a biotechnology business based in the US. Decibel Therapeutics shares (DBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Decibel Therapeutics employs 62 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.24 |
|---|---|
| 52-week range | $1.83 - $9.75 |
| 50-day moving average | $2.27 |
| 200-day moving average | $4.70 |
| Wall St. target price | $16.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.24 from 2022-06-27
| 1 week (2022-06-21) | -3.45% |
|---|---|
| 1 month (2022-05-27) | -4.27% |
| 3 months (2022-03-29) | -23.81% |
| 6 months (2021-12-29) | -52.54% |
| 1 year (2021-06-29) | -75.00% |
|---|---|
| 2 years (2020-06-25) | N/A |
| 3 years (2019-06-25) | N/A |
| 5 years (2017-06-25) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.51% |
| Return on equity TTM | -35.65% |
| Profit margin | 0% |
| Book value | $5.13 |
| Market capitalisation | $62.2 million |
TTM: trailing 12 months
We're not expecting Decibel Therapeutics to pay a dividend over the next 12 months.
Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV. 201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV. 103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.